Growing out of the old self: management itself says the company has quietly become a different business, and the numbers
The model's full reasoning — Q2 2022 call → NOThe question asks whether management conveys that the company is running on a different basis than its reported results and reputation were built on — that is, whether management describes the company as having crossed into being a different kind of business, while making clear that this change is not yet reflected in reported numbers or outside perception. Let me analyze the transcript carefully. Key elements: 1. Management discusses the CDMO business extensively, describing it as a new business for them, an adjacency, similar to the Early Discovery acquisition in 2014. They say it's "a new business for us" and "it's new for the world." They describe the integration of Cognate and Vigene acquisitions, creating centers of excellence. 2. However, the question is whether management conveys that the company as a whole has crossed into being a different kind of business, with the reported results and reputation lagging that change. Let me look for specific language about the company's basis changing: - Jim Foster says: "We are making good progress bringing our cell and gene therapy services together and working towards these businesses becoming fully integrated within themselves and with our broader portfolio." - He says: "Like Early Discovery, we believe our CDMO business is an integral part of our essential portfolio because it enables clients to access a comprehensive solution for cell and gene therapy, research development and production from one scientific partner." - He says: "We have built an excellent foundation for cell and gene therapy solutions since 2020 through M&A and we will focus on integrating these enhanced scientific capabilities as well as all of our recent acquisitions." - He says: "We believe that CDMO growth opportunity remains robust, that we have the right scientific capabilities in place to be a uniquely ideal partner for our clients." But is this a "change of basis" for the company as a whole? The CDMO business is one segment (manufacturing), and it's actually underperforming. The company's core businesses (DSA, RMS) are performing well on the same basis as before.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
CALX · Q1 2023 → YESThe question is whether management conveys that the company today is running on a different basis than what its reported results and reputation were built on. Both parts: a change of basis already rea...YES The transcript shows management describing the company as now operating on a fundamentally different basis—selling into a new market of broadband service providers building consolidated networks, shifting from a legacy cyclical model to sequential revenue through platforms, clouds, and managed services—while treating this as an accomplished reality today, not a future plan. They emphasize numbers like 988 BSP deployments, 865 cloud customers, and 334 managed services customers, along with three years of over 25% growth, as evidence of this new foundation already in place.
SANG · Q2 2024 → YESThe question is whether management conveys that the company today is running on a different basis than the one its reported results and reputation were built on. Both parts: a real change of basis alr...
WD · Q2 2022 → YESThe question is whether management conveys that the company today is running on a different basis than the company its reported results and reputation were built on. Specifically, two parts: a change ...